DS Healthcare Group, Inc. is preparing to submit to the United States Food and Drug Administration (FDA) an Investigational New Drug Application (IND) for its proprietary topical hair loss treatment. On Oct. 29, 2013 the company announced it had filed a patent with the US Patent and Trademark Office for the invention. An IND is a request for the FDA's authorization to administer an investigational drug to humans and is the first step toward designing and conducting clinical trials in the US...